Orano med

Focus: Orano med is an early-stage oncology biotech focused on alpha-emitter radiotherapeutics for cancer treatment. The company operates from Plano, TX with a lean team actively hiring across 21 open roles.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Orano med

AI assessmentNot Hiring

No open roles listed right now. Follow Orano med to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AlphaMedix

Neuroendocrine Tumor

Phase 1

Clinical Trials (1)

NCT03466216Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

Phase 1

Help build intelligence for Orano med

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering alpha-emitter radiotherapy modality addressing underserved oncology indications with lead programs in cervical cancer, breast cancer, and neuroendocrine tumors
Early-stage pipeline (3 Phase 1 trials active) offers significant upside potential if lead programs advance, providing high career leverage for core contributors
Actively hiring across 21 roles signals expansion phase and opportunity to build functions from the ground up

Watch Out For

No approved products and no disclosed revenue means zero cash generation—entirely dependent on external funding not disclosed in available data
All programs remain in Phase 1/early Phase 2 with no Phase 3 data, creating 5-7+ year timeline to any potential approval and substantial clinical risk
No disclosed financial metrics, funding history, or employee count limits visibility into burn rate, runway, and organizational stability

Generated by Claude from Orano med's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

²¹²Pb-DOTAM-GRPR1

Cervical Cancer

Phase 1

Clinical Trials (1)

NCT05283330Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Phase 1

²¹²Pb-TCMC-Trastuzumab

Breast Neoplasms

Phase 1

Clinical Trials (1)

NCT01384253Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Phase 1